D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery

[1]  W. Hohenberger,et al.  D3 lymph node dissection in gastric cancer: Evaluation of postoperative mortality and complications , 2010, Surgery Today.

[2]  T. Eberlein.  D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer , 2009 .

[3]  Judy L. Smith,et al.  Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  F. Tanaka.  UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction , 2007, Surgery Today.

[5]  Toshio Shimizu,et al.  Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501. , 2007, Japanese journal of clinical oncology.

[6]  H. Yamamoto,et al.  Metastasis in para-aortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. , 2007, Hepato-gastroenterology.

[7]  H. Shimada,et al.  Surgical outcome of para-aortic lymph node dissection preserving neural tissue based on anatomical evaluations , 2005, Journal of Gastrointestinal Surgery.

[8]  M. Sierzega,et al.  Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. , 2007, American journal of surgery.

[9]  M. Yano,et al.  Postoperative Gastrointestinal Dysfunction after 2-field Versus 3-field Lymph Node Dissection in Patients with Esophageal Cancer , 2007, Surgery Today.

[10]  S. Takashima,et al.  Paraaortic lymph node dissection for gastric cancer in 244 consecutive cases. , 2006, Hepato-gastroenterology.

[11]  H. Yamamoto,et al.  Operative morbidity and mortality after D2 and D4 extended dissection for advanced gastric cancer: a prospective randomized trial conducted by Asian surgeons. , 2006, Hepato-gastroenterology.

[12]  M. Posner,et al.  D3 or not D3... that is not the question. , 2006, The Lancet. Oncology.

[13]  Jen-Hao Chen,et al.  Nodal dissection for patients with gastric cancer: a randomised controlled trial. , 2006, The Lancet. Oncology.

[14]  H. Shimada,et al.  Comparison of Surgical Results of D2 Versus D3 Gastrectomy (Para-Aortic Lymph Node Dissection) for Advanced Gastric Carcinoma: A Multi-Institutional Study , 2006, Annals of surgical oncology.

[15]  F. Roviello,et al.  Complications after Extended (D2) and Superextended (D3) Lymphadenectomy for Gastric Cancer: Analysis of Potential Risk Factors , 2006, Annals of Surgical Oncology.

[16]  K. Mafune,et al.  Safety of a paraaortic node dissection for selected advanced gastric cancer patients. , 2005, Hepato-gastroenterology.

[17]  A. Nashimoto,et al.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Takashima,et al.  Results and Controversial Issues Regarding a Para-Aortic Lymph Node Dissection for Advanced Gastric Cancer , 2004, Surgery Today.

[19]  H. Shimada,et al.  Implication of extended lymph node dissection stratified for advanced gastric cancer. , 2003, Anticancer research.

[20]  C. Kunisaki,et al.  Significance of para-aortic lymph node dissection in advanced gastric cancer. , 1999, Hepato-gastroenterology.

[21]  M. Huguier,et al.  [Extended lymph-node dissection for gastric cancer]. , 1999, Chirurgie; memoires de l'Academie de chirurgie.

[22]  H. Saito,et al.  Effects of super-extended paraaortic lymphadenectomy (PAL) on biological responses in totally gastrectomized patients with T3 or T4 gastric cancer , 1998, Gastric Cancer.

[23]  P. Fayers,et al.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial , 1996, The Lancet.

[24]  J. Hermans,et al.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients , 1995, The Lancet.

[25]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .